Drug Approval | January 23, 2024
EMA grants ODD to GC Biopharma's treatment for Sanfilippo Syndrome
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Evinova will operate as a separate health-tech business within AstraZeneca
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
The collaboration brings a seamless digital experience to more formulators worldwide
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
Subscribe To Our Newsletter & Stay Updated
